Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: NOW who wrote (2825)	10/19/2005 8:48:57 PM
From: Maurice Winn	Read Replies (2) \| Respond to of 4232

<meaning the mortality rate is much lower than 60%> Wishful thinking and much too early to draw that conclusion. They are purely guessing that infections are the tip of the iceberg. They have no evidence. If mortality is actually only 20% and that includes treatment with Tamiflu etc, then it is still not exactly good news. Because what do you think will happen when Tamiflu and other treatments run out of stock? Yes, the mortality rate will go right back up to the "untreated" rate, which is nearer 70%, unless we get a lucky natural attenuation of the bug so it kills fewer people. Luck isn't an essential ingredient in the way natural selection works. Nature doesn't love us. We are just dinners which haven't been eaten yet. Mqurice